Alternative Data for Cassava Sciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 76 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 30 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 52,743 | Sign up | Sign up | Sign up |
| X Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | N/A | Sign up | Sign up | Sign up |
About Cassava Sciences
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
| Price | $2.09 |
| Target Price | Sign up |
| Volume | 467,350 |
| Market Cap | $142M |
| Year Range | $1.75 - $4.64 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s DiseaseJanuary 12 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 840,000 | 200,000 | -200,000 | -11M | -11M | -0.220 |
| Q2 '25 | 0 | 5.1M | -5.1M | -44M | -14M | -0.920 |
| Q1 '25 | 0 | 14M | -14M | -23M | -21M | -0.485 |
| Q4 '24 | 1.2M | 21M | -21M | -28M | -19M | -0.570 |
| Q3 '24 | 0 | 18M | -18M | -28M | -31M | -0.580 |
Insider Transactions View All
| Anderson Robert Eugene Jr filed to buy 8,600 shares at $2.9. November 25 '25 |
| Barry Richard filed to buy 938,060 shares at $2.8. November 24 '25 |
| Barry Richard filed to buy 788,060 shares at $2.8. November 20 '25 |
| Cook Robert Christopher filed to buy 13,725 shares at $2.9. October 2 '25 |
| Barry Richard filed to buy 714,675 shares at $2.3. September 23 '25 |
Similar companies
Read more about Cassava Sciences (SAVA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Cassava Sciences
The Market Cap of Cassava Sciences is $142M.
Currently, the price of one share of Cassava Sciences stock is $2.09.
The SAVA stock price chart above provides a comprehensive visual representation of Cassava Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cassava Sciences shares. Our platform offers an up-to-date SAVA stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Cassava Sciences (SAVA) does not offer dividends to its shareholders. Investors interested in Cassava Sciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Cassava Sciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
